Today's Date: June 3, 2023
Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam   •   LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemo   •   High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy   •   Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery   •   KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line   •   Statement from Minister Hutchings on progress in support of rural Canadians   •   UNice Celebrates LGBTQ Pride Month   •   Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i   •   GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting   •   Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting   •   Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i   •   Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin   •   New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing   •   56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award   •   Government of Canada releases summary of actions taken to address the safety and wellbeing of Indigenous women, girls and 2SLGBT   •   Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Cl   •   San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf   •   Bijou Ikli named new CEO by Florida Assisted Living Association
Bookmark and Share

U Of Illinois Starts Program To Study Cell Pain

 Researchers at the University of Illinois at Chicago will use a $2 million federal grant to investigate why patients with sickle cell disease experience chronic pain -- and to develop drugs to treat it. 

The neurobiology of pain in sickle cell disease is poorly understood, said Z. Jim Wang, associate professor of pharmacology and pharmaceutics and lead researcher on the four-year study. Research has been conducted using several animal models, but the findings were limited, he said. 

In preliminary studies conducted at UIC, Wang and his team observed that CaMKII, an enzyme called a protein kinase that plays an important role in the generation and maintenance of opioid addiction, is a critical component leading to persistent pain. Several pain tests -- some that are employed in ongoing human studies of sickle cell disease using quantitative sensory testing -- will be used on mouse models, Wang said.

Affecting more than 70,000 Americans, sickle cell disease causes red blood cells to become hard and pointed instead of soft and round. Sickle cell disease can damage lung tissue and cause excruciating pain and stroke. The blockage of blood flow caused by sickled cells also causes damage to most organs, including the spleen, kidneys and liver. About 2.5 million Americans have the sickle cell trait. 

UIC researchers will examine the expression and activity of CaMKII in mice carrying human sickle mutations and test the hypothesis that spinal CaMKII is a "molecular mechanism that promotes and maintains the manifestation of chronic pain in sickle cell disease," Wang said. 

Following the initial studies, Wang and his research team will conduct pharmacological studies using an FDA-approved oral antipsychotic prescription medication -- trifluoperazine -- that is found to be a CaMKII inhibitor that reduces inflammatory and neuropathic pain. The phase I work will be performed in humans with sickle cell disease, he said. 

Wang's coworkers include Diana Wilkie, professor of biobehavioral health science; Robert Molokie, instructor in medicine; and Joseph Desimone, director of the UIC Sickle Cell Center. The study is funded by the National Heart, Lung and Blood Institute, one of the National Institutes of Health. 

For more information about UIC, visit

University of Illinois at Chicago Office of Public Affairs (MC 288)
601 S. Morgan St., Chicago, IL 60607-7113, (312) 996-3456,

Sam Hostettler, (312) 355-2522,



Back to top
| Back to home page

White House Live Stream
Breaking News
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News